131 related articles for article (PubMed ID: 11741487)
1. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.
Jakobsen CM; Denmeade SR; Isaacs JT; Gady A; Olsen CE; Christensen SB
J Med Chem; 2001 Dec; 44(26):4696-703. PubMed ID: 11741487
[TBL] [Abstract][Full Text] [Related]
2. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
Christensen SB; Andersen A; Kromann H; Treiman M; Tombal B; Denmeade S; Isaacs JT
Bioorg Med Chem; 1999 Jul; 7(7):1273-80. PubMed ID: 10465403
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: complex regulation by intracellular calcium.
Dubois C; Vanden Abeele F; Sehgal P; Olesen C; Junker S; Christensen SB; Prevarskaya N; Møller JV
FEBS J; 2013 Nov; 280(21):5430-40. PubMed ID: 23927406
[TBL] [Abstract][Full Text] [Related]
4. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR
Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783
[TBL] [Abstract][Full Text] [Related]
5. Structure/activity relationship of thapsigargin inhibition on the purified Golgi/secretory pathway Ca
Chen J; De Raeymaecker J; Hovgaard JB; Smaardijk S; Vandecaetsbeek I; Wuytack F; Møller JV; Eggermont J; De Maeyer M; Christensen SB; Vangheluwe P
J Biol Chem; 2017 Apr; 292(17):6938-6951. PubMed ID: 28264934
[TBL] [Abstract][Full Text] [Related]
6. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.
Christensen SB; Skytte DM; Denmeade SR; Dionne C; Møller JV; Nissen P; Isaacs JT
Anticancer Agents Med Chem; 2009 Mar; 9(3):276-94. PubMed ID: 19275521
[TBL] [Abstract][Full Text] [Related]
7. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
Vander Griend DJ; Antony L; Dalrymple SL; Xu Y; Christensen SB; Denmeade SR; Isaacs JT
Mol Cancer Ther; 2009 May; 8(5):1340-9. PubMed ID: 19417145
[TBL] [Abstract][Full Text] [Related]
8. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells.
Søhoel H; Jensen AM; Møller JV; Nissen P; Denmeade SR; Isaacs JT; Olsen CE; Christensen SB
Bioorg Med Chem; 2006 Apr; 14(8):2810-5. PubMed ID: 16412648
[TBL] [Abstract][Full Text] [Related]
9. Critical roles of hydrophobicity and orientation of side chains for inactivation of sarcoplasmic reticulum Ca2+-ATPase with thapsigargin and thapsigargin analogs.
Winther AM; Liu H; Sonntag Y; Olesen C; le Maire M; Soehoel H; Olsen CE; Christensen SB; Nissen P; Møller JV
J Biol Chem; 2010 Sep; 285(37):28883-92. PubMed ID: 20551329
[TBL] [Abstract][Full Text] [Related]
10. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer.
Denmeade SR; Isaacs JT
Cancer Biol Ther; 2005 Jan; 4(1):14-22. PubMed ID: 15662118
[TBL] [Abstract][Full Text] [Related]
11. Design and total synthesis of unnatural analogues of the sub-nanomolar SERCA inhibitor thapsigargin.
Andrews SP; Tait MM; Ball M; Ley SV
Org Biomol Chem; 2007 May; 5(9):1427-36. PubMed ID: 17464412
[TBL] [Abstract][Full Text] [Related]
12. Targeting thapsigargin towards tumors.
Doan NT; Paulsen ES; Sehgal P; Møller JV; Nissen P; Denmeade SR; Isaacs JT; Dionne CA; Christensen SB
Steroids; 2015 May; 97():2-7. PubMed ID: 25065587
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
14. ACTA, a fluorescent analogue of thapsigargin, is a potent inhibitor and a conformational probe of skeletal muscle Ca2+-ATPase.
Procida K; Caspersen C; Kromann H; Christensen SB; Treiman M
FEBS Lett; 1998 Nov; 439(1-2):127-32. PubMed ID: 9849892
[TBL] [Abstract][Full Text] [Related]
15. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.
Furuya Y; Lundmo P; Short AD; Gill DL; Isaacs JT
Cancer Res; 1994 Dec; 54(23):6167-75. PubMed ID: 7954463
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.
Lee DI; Sumbilla C; Lee M; Natesavelalar C; Klein MG; Ross DD; Inesi G; Hussain A
Arch Biochem Biophys; 2007 Aug; 464(1):19-27. PubMed ID: 17475205
[TBL] [Abstract][Full Text] [Related]
17. Role of endoplasmic reticulum calcium content in prostate cancer cell growth regulation by IGF and TNFalpha.
Humez S; Legrand G; Vanden-Abeele F; Monet M; Marchetti P; Lepage G; Crepin A; Dewailly E; Wuytack F; Prevarskaya N
J Cell Physiol; 2004 Nov; 201(2):201-13. PubMed ID: 15334655
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a role of the sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase in thapsigargin and Bcl-2 induced changes in Xenopus laevis oocyte maturation.
Kobrinsky EM; Kirchberger MA
Oncogene; 2001 Feb; 20(8):933-41. PubMed ID: 11314028
[TBL] [Abstract][Full Text] [Related]
19. Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.
Singh P; Mhaka AM; Christensen SB; Gray JJ; Denmeade SR; Isaacs JT
J Med Chem; 2005 Apr; 48(8):3005-14. PubMed ID: 15828839
[TBL] [Abstract][Full Text] [Related]
20. Depletion of intracellular calcium stores is toxic to SH-SY5Y neuronal cells.
Nguyen HN; Wang C; Perry DC
Brain Res; 2002 Jan; 924(2):159-66. PubMed ID: 11750901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
